Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

Inclusion Criteria:

   - >/= 18 years-old

   - Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or

   - Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and
   followed primarily by SHC Blood and Bone Marrow transplant providers

   - >/= 6 months from the date of CAR-T infusion

   - Fluent in English

   - Able to attend and participate in in-person testing (Arm I)

   - Able to participate in remote video testing with adequate workspace, computer and
   internet capabilities for a reliable telehealth video connection (Arm II)

Exclusion Criteria:

   - Concurrent enrollment in a CAR-T therapeutics research study

   - Unable to be present for the scheduled testing

   - Unable to participate in testing due to severe cognitive or physical limitation

   - Actively receiving chemotherapy

   - Progressive cancer